Biotech Analyst Mukherjee discusses Wilson’s Disease with an Monopar Therapeutics (MNPR) ALXN1840 investigator on an Analyst/Industry conference call to be held on November 3 at 11 am.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics Advances Cancer Treatment with New Dose-Escalation Study
- Monopar Therapeutics’ Innovative Imaging Agent Study: Market Implications
- Monopar Therapeutics initiated with an Overweight at Barclays
- Monopar Therapeutics Inc.: Promising Prospects with ALXN1840 Acquisition and Wilson’s Disease Market Potential
- Monopar Therapeutics price target raised to $142 from $80 at Raymond James